研究者業績
基本情報
- 所属
- 藤田医科大学 医学部 医学科 先端光学診療学講座
- 学位
- 博士(医学）
- J-GLOBAL ID
- 200901011108502975
- researchmap会員ID
- 6000005568
患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。
研究キーワード
8研究分野
1委員歴
28-
2024年2月 - 現在
-
2023年2月 - 現在
-
2022年9月 - 現在
受賞
4-
2022年10月
-
2019年10月
-
2015年10月
論文
270-
The Journal of dermatology 2024年9月30日 査読有り
-
JAMA 2024年7月22日 査読有りImportance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. Objective To evaluate the efficacy and safety of risankizumab when administered as an induction and a maintenance therapy for patients with ulcerative colitis. Design, Setting, and Participants Two phase 3 randomized clinical trials were conducted. The induction trial was conducted at 261 clinical centers (in 41 countries) and enrolled 977 patients from November 5, 2020, to August 4, 2022 (final follow-up on May 16, 2023). The maintenance trial was conducted at 238 clinical centers (in 37 countries) and enrolled 754 patients from August 28, 2018, to March 30, 2022 (final follow-up on April 11, 2023). Eligible patients had moderately to severely active ulcerative colitis; a history of intolerance or inadequate response to 1 or more conventional therapies, advanced therapies, or both types of therapies; and no prior exposure to risankizumab. Interventions For the induction trial, patients were randomized 2:1 to receive 1200 mg of risankizumab or placebo administered intravenously at weeks 0, 4, and 8. For the maintenance trial, patients with a clinical response (determined using the adapted Mayo score) after intravenous treatment with risankizumab were randomized 1:1:1 to receive subcutaneous treatment with 180 mg or 360 mg of risankizumab or placebo (no longer receiving risankizumab) every 8 weeks for 52 weeks. Main Outcomes and Measures The primary outcome was clinical remission (stool frequency score ≤1 and not greater than baseline, rectal bleeding score of 0, and endoscopic subscore ≤1 without friability) at week 12 for the induction trial and at week 52 for the maintenance trial. Results Among the 975 patients analyzed in the induction trial (aged 42.1 [SD, 13.8] years; 586/973 [60.1%] were male; and 677 [69.6%] were White), the clinical remission rates at week 12 were 132/650 (20.3%) for 1200 mg of risankizumab and 20/325 (6.2%) for placebo (adjusted between-group difference, 14.0% [95% CI, 10.0%-18.0%], P < .001). Among the 548 patients analyzed in the maintenance trial (aged 40.9 [SD, 14.0] years; 313 [57.1%] were male; and 407 [74.3%] were White), the clinical remission rates at week 52 were 72/179 (40.2%) for 180 mg of risankizumab, 70/186 (37.6%) for 360 mg of risankizumab, and 46/183 (25.1%) for placebo (adjusted between-group difference for 180 mg of risankizumab vs placebo, 16.3% [97.5% CI, 6.1%-26.6%], P < .001; adjusted between-group difference for 360 mg of risankizumab vs placebo, 14.2% [97.5% CI, 4.0%-24.5%], P = .002). No adverse event signals were detected in the treatment groups. Conclusion and Relevance Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis. Further study is needed to identify benefits beyond the 52-week follow-up. Trial Registration ClinicalTrials.gov Identifiers: NCT03398148 and NCT03398135
-
Journal of gastrointestinal and liver diseases : JGLD 33(2) 164-169 2024年6月29日 査読有りBACKGROUND AND AIMS: Early gastric cancers (EGCs) after Helicobacter pylori (H. pylori) eradication often appear as reddish depressed lesions (RDLs); the same features are also appeared in benign stomachs after eradication. We compared clinic-pathological and endoscopic features of benign and neoplastic RDLs after H. pylori eradication. METHODS: 228 neoplastic RDLs after H. pylori eradication were studied. All lesions were divided into neoplastic RDLs (differentiated carcinoma or adenoma, n=114) and benign RDLs (n=114) according to the histology. Clinical and pathological characteristics were compared in neoplastic and benign groups. Endoscopic diagnostic yields using the white light (WL) endoscopy, chromoendoscopy (CE) using indigo carmine dye and the magnifying endoscopy with narrow-band imaging (ME-NBI) were also evaluated in relation to the pathological diagnosis. RESULTS: Size of neoplastic RDLs was larger than that of benign RDLs (p<0.01). Sensitivity, specificity and accuracy for predicting pathological types of RDLs was 70.1%, 52.6% and 61.4% for the WL, 65.8%, 63.1% and 65.4% for the CE, while the ME-NBI scored better with the 88.6%, 88.6%, 99.1% and 93.9% of sensitivity, specificity and accuracy. The accuracy of the ME-NBI was 99.9% (113/114) in the benign RDLs and 89.4% (101/114) for the neoplastic RDLs. Undiagnosed neoplastic RDLs using the ME-NBI were associated with more differentiated tumors such as adenoma and well-differentiated adenocarcinoma (tub1) and the presence of an unclear demarcation line. CONCLUSIONS: ME-NBI is useful to diagnose RDLs after H. pylori eradiation, while some of neoplastic lesions are difficult to diagnose using the ME-NBI.
-
Journal of gastroenterology 59(5) 376-388 2024年5月 査読有りBACKGROUND: The clinicopathological features and prognosis of primary small bowel adenocarcinoma (PSBA), excluding duodenal cancer, remain undetermined due to its rarity in Japan. METHODS: We analyzed 354 patients with 358 PSBAs, between January 2008 and December 2017, at 44 institutions affiliated with the Japanese Society for Cancer of the Colon and Rectum. RESULTS: The median age was 67 years (218 males, 61.6%). The average tumor size was 49.9 (7-100) mm. PSBA sites consisted of jejunum (66.2%) and ileum (30.4%). A total of 219 patients (61.9%) underwent diagnostic small bowel endoscopy, including single-balloon endoscopy, double-balloon endoscopy, and capsule endoscopy before treatment. Nineteen patients (5.4%) had Lynch syndrome, and 272 patients (76.8%) had symptoms at the initial diagnosis. The rates for stages 0, I, II, III, and IV were 5.4%, 2.5%, 27.1%, 26.0%, and 35.6%, respectively. The 5-year overall survival rates at each stage were 92.3%, 60.0%, 75.9%, 61.4%, and 25.5%, respectively, and the 5-year disease-specific survival (DSS) rates were 100%, 75.0%, 84.1%, 59.3%, and 25.6%, respectively. Patients with the PSBA located in the jejunum, with symptoms at the initial diagnosis or advanced clinical stage had a worse prognosis. However, multivariate analysis using Cox-hazard model revealed that clinical stage was the only significant predictor of DSS for patients with PSBA. CONCLUSIONS: Of the patients with PSBA, 76.8% had symptoms at the initial diagnosis, which were often detected at an advanced stage. Detection during the early stages of PSBA is important to ensure a good prognosis.
-
日本消化器病学会雑誌 121(臨増総会) A190-A190 2024年3月
MISC
1258-
Oncology reports 31(4) 1883-90 2014年4月 査読有りThe mechanisms of drug resistance in cancer are not fully elucidated. To study the drug resistance of gastric cancer, we analyzed gene expression and DNA methylation profiles of 5-fluorouracil (5-FU)- and cisplatin (CDDP)-resistant gastric cancer cells and biopsy specimens. Drug-resistant gastric cancer cells were established with culture for >10 months in a medium containing 5-FU or CDDP. Endoscopic biopsy specimens were obtained from gastric cancer patients who underwent chemotherapy with oral fluoropyrimidine S-1 and CDDP. Gene expression and DNA methylation analyses were performed using microarray, and validated using real-time PCR and pyrosequencing, respectively. Out of 17,933 genes, 541 genes commonly increased and 569 genes decreased in both 5-FU- and CDDP-resistant AGS cells. Genes with expression changed by drugs were related to GO term 'extracellular region' and 'p53 signaling pathway' in both 5-FU- and CDDP-treated cells. Expression of 15 genes including KLK13 increased and 12 genes including ETV7 decreased, in both drug-resistant cells and biopsy specimens of two patients after chemotherapy. Out of 10,365 genes evaluated with both expression microarray and methylation microarray, 74 genes were hypermethylated and downregulated, or hypomethylated and upregulated in either 5-FU-resistant or CDDP-resistant cells. Of these genes, expression of 21 genes including FSCN1, CPT1C and NOTCH3, increased from treatment with a demethylating agent. There are alterations of gene expression and DNA methylation in drug-resistant gastric cancer; they may be related to mechanisms of drug resistance and may be useful as biomarkers of gastric cancer drug sensitivity.
-
Intestine 18(2) 145-150 2014年3月2012年7月パテンシーカプセルが保険収載され,クローン病に対してカプセル内視鏡が施行可能となり1年以上が経過した.パテンシーカプセルやカプセル内視鏡の偶発症も報告されており,適応・禁忌について熟知する必要はあるが,カプセル内視鏡で初めて小腸病変の活動性が判明する症例をしばしば経験する.カプセル内視鏡は放射線被曝や苦痛なく小腸粘膜病変の評価が可能であり,クローン病小腸病変のスクリーニング,フォローアップに有用であると考える.(著者抄録)
-
胃と腸 49(3) 385-393 2014年3月患者は62歳,女性.20歳時に関節リウマチ(RA)を発症しており,最近5年間は無治療で放置していた.慢性下痢,食欲不振,体重減少を主訴に来院した.消化管内視鏡検査で上行結腸から直腸に連続性,びまん性に浮腫状,発赤調,微細顆粒状を呈する粘膜と厚い白苔を有する多発性・大小不同の不整型潰瘍が認められた.また,十二指腸には微細顆粒状の粘膜と多発するびらんが認められた.生検にてアミロイド蛋白の沈着を認め,RAに合併したAAアミロイドーシスと診断した.抗IL-6受容体抗体(トシリズマブ)の投与により,臨床症状とともに,内視鏡・病理所見の改善が認められた.トシリズマブはRAに合併したAAアミロイドーシスの有効な治療法であると考えられた.(著者抄録)
-
HEPATO-GASTROENTEROLOGY 61(130) 525-528 2014年3月 査読有りBackground/Aims: Combining the magnifying endoscopy and the narrow-band imaging (NBI) system is an endoscopic imaging technique for the enhanced visualization of mucosal microscopic structure and capillaries of the superficial mucosal layer. Light blue crest (LBC) and, ridge/villous pattern have been thought to be suggestive signs for gastric intestinal metaplasia (IM) of magnifying NBI endoscopy. Since the IM is related to gastric cancer risk (GC), the prevalence of LBC and ridge/villous pattern in the nonneoplastic gastric antrum was examined in relation to gastric cancer (GC) risk and serological severity of gastritis. Methodology: In 100 subjects including 13 GC patients, gastric mucosal pattern were examined using magnifying NBI. The mucosal patterns in the antrum were classified according to the presence of LBC or ridge/villous pattern. Serum pepsinogen (PG) levels were also examined. Results: The sensitivity and specificity for predicting IM was the best when LBC and ridge/villous patterns were combined (sensitivity 95.2%, specificity 98.7%). Both LBC and ridge/villous pattern showed lower serum PGI and PGI/II ratio than those without (P = 0.046, 0.0005, respectively.) In particular, PGI/II ratio was lowest in ridge/villous pattern. The LBC and ridge/villous pattern showed higher incidence of all GC and diffuse GC compared to those without (P = 0.002, 0.002, respectively). Conclusions: LBC and ridge/villous pattern in uninvolved gastric antrum by magnifying NBI endoscopy are useful signs for predicting gastric atrophy in the entire Stomach and GC risk.
-
Gastrointestinal endoscopy 79(2) 335-6 2014年2月 査読有り
-
Journal of gastroenterology and hepatology 29(1) 96-101 2014年1月 査読有りBackground and AimUntil the approval of patency capsule, capsule endoscopy (CE) has not been routinely applied for the diagnosis of Crohn's disease (CD) in Japan. We aimed to survey current situation of CE use for patients with CD in Japan. MethodsThe nationwide survey of 40 Japanese institutions identified 94 patients with established CD (eCD) and 80 patients with suspected CD (sCD), who were examined by CE. Types and positive rates of mucosal injury under CE and capsule retention rate were investigated. In sCD, final diagnosis after CE was also analyzed. ResultsPatients with eCD comprised 82 patients of ileitis or ileocolitis type, while 12 patients had CD of colitis type. CE identified mucosal injuries in 83 of 94 patients. Eight of 12 patients with eCD of colitis type had ileal lesions under CE, thereby being reclassified as ileocolitis type. In patients with sCD, CE detected mucosal injuries in 58 patients. Linear ulceration and cobblestone appearance were depicted in 22 and 3 patients, respectively, thereby resulting in established diagnosis of CD in 23 patients. Mucosal lesion was not found in 22 patients with sCD, who were diagnosed as not having CD. Capsule retention rate was not statistically different between patients with eCD and those with sCD (7.4% vs 6.3%, P=1.0). ConclusionsCE is useful for the evaluation of small bowel mucosal injuries in Japanese patients with sCD and eCD. Possible intestinal stricture needs to be carefully evaluated before CE even in patients with sCD.
-
Intestine 17(6) 547-552 2013年11月パテンシーカプセルの導入により,クローン病に対してカプセル内視鏡が施行可能となって約1年が経過する.パテンシーカプセル・カプセル内視鏡検査は適応・禁忌を十分に理解したうえで使用すれば,低侵襲かつ高感度にクローン病小腸粘膜病変を評価でき,粘膜治癒を目指すうえで非常に有用な検査となる.とくに,クローン病小腸病変の有無や治療効果判定などにカプセル内視鏡検査は有用である.(著者抄録)
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 28 146-147 2013年10月
-
Japanese journal of clinical oncology 43(10) 964-71 2013年10月 査読有りThis Phase II trial was designed to evaluate the safety and efficacy of neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy in patients with poor-risk rectal cancer. Patients with magnetic resonance imaging-defined poor-risk rectal cancer received neoadjuvant oxaliplatin and capecitabine and bevacizumab followed by total mesorectal excision or more extensive surgery. Between February 2010 and December 2011, 32 patients were enrolled in this study. The completion rate of the scheduled chemotherapy was 91. Reasons for withdrawal were refusal to continue therapy in two patients and disease progression in one, with two of these three patients not undergoing surgery. Among the 29 patients who completed the scheduled chemotherapy, one refused surgery within 8 weeks after the completion of chemotherapy, which was the period stipulated by the protocol, and another had rectal perforation, requiring urgent laparotomy. As a result, the completion rate of this experimental treatment was 84. Of the 30 patients who underwent surgery, the R0 resection rate was 90 and a postoperative complication occurred in 43. A pathological complete response was observed in 13 and good tumor regression was exhibited in 37. Neoadjuvant oxaliplatin and capecitabine plus bevacizumab for poor-risk rectal cancer caused a high rate of anastomotic leakage and experienced a case with perforation during chemotherapy, both of which were bevacizumab-related toxicity. Although the short-term results with the completion rate of 84.4 and the pathological complete response rate of 13.3 were satisfactory, we have to reconsider the necessity of bevacizumab in neoadjuvant chemotherapy (UMIN number, 000003507).
-
Gastroenterological Endoscopy 55(Suppl.2) 2632-2632 2013年9月
-
Gastroenterological Endoscopy 55(Suppl.2) 2838-2838 2013年9月
-
Surgery today 43(9) 1062-5 2013年9月 査読有りThe clinical introduction of double-balloon endoscopy (DBE) has brought about a revolution in the diagnosis and the treatment of diseases of the small intestine. DBE allows not only direct observation of the entire small intestine, but also interventional therapies, tissue sampling and India ink marking (tattooing). Single incision laparoscopic surgery (SILS) was developed from conventional laparoscopic surgery to further reduce the degree of invasiveness. SILS requires only one umbilical incision, thus resulting in almost scarless surgery. This report presents three cases of small intestinal bleeding successfully treated by SILS following tattooing under DBE. The average operative time was 67 min and average blood loss was 5 ml. All patients immediately recovered without any complications. SILS, in conjunction with presurgical tattooing by DBE for small intestinal bleeding is considered to be an ideal approach in terms of minimal surgical trauma and aesthetics.
-
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 34(7) 1241-6 2013年9月 査読有りObjective: Acute low-tone sensorineural hearing loss (ALHL) has been reported to be associated with endolymphatic hydrops (EHs). However, evaluation of the size of the endolymphatic space has not been reported. We attempted to visualize EH in ALHL using magnetic resonance imaging (MRI). Study Design: Prospective diagnostic study. Setting: University hospital. Methods: We evaluated 25 ears of 25 unilateral ALHL patients. Three-tesla MRI was obtained 24 hours after intratympanic injection of gadolinium (Gd) (n = 5) or 4 hours after intravenous injection of Gd (n = 20). A radiologist blinded to the patients' clinical data classified the degree of EH in the vestibule and cochlea into 3 groups: none, mild, and significant. Results: On the affected sides, cochlear EH was recognized in 23 ears (92%) and was classified as significant EH (n = 15) or mild EH (n = 8); vestibular EH was detected in 22 ears (88%), classified as significant EH (n = 16) or mild EH (n = 6). Cochlear EH was more frequently observed in the affected ear than in the contralateral ear (90% versus 40%, p < 0.05). Conclusion: In ALHL, EH was observed not only in the cochlea but also in the vestibule as in Meniere's disease.
-
Nagoya journal of medical science 75(3-4) 273-8 2013年8月Hepatic portal venous gas is a rare condition that occurs when intraluminal gas or gas produced by intestinal bacteria enters the portal venous circulation. It has recently been recognized as a rare complication of colon procedures by endoscopy or barium enema. Given the frequency of these procedures in patients with inflammatory bowel disease, hepatic portal venous gas may occur more frequently in these patients than previously reported. Here, we report a woman with Crohn's disease who developed hepatic portal venous gas following colonoscopy who was treated with conservative therapy.
-
胃と腸 48(8) 1176-1182 2013年7月非腫瘍性大腸ポリポーシスは腫瘍性病変に比して頻度は低いが,多彩な疾患が含まれる.遺伝性ポリポーシスと非遺伝性ポリポーシスに大別され,それぞれ特徴的な形態や分布をとるため,内視鏡所見が診断の決め手となることが多い.非腫瘍性大腸ポリポーシスは大腸以外の消化管や消化管外臓器に病変が生じたり,消化管ポリープが腸重積や腫瘍を合併したりする場合があるため,患者を検査・診療する前にあらかじめその疾患に精通しておく必要がある.(著者抄録)
-
消化器内視鏡 25(7) 943-951 2013年7月以前「暗黒大陸」と言われた小腸領域の診断法・治療法は、各種検査技術の革新により進歩した。特に、小腸内視鏡はカプセル内視鏡とバルーン内視鏡の出現により目覚ましく発展した領域である。そのおかげでさまざまな小腸疾患が的確に診断され、低侵襲に治療できるようになった。本稿では、臨床現場で遭遇しうる小腸出血、小腸狭窄、小腸腫瘍、蛋白漏出性腸症の病態を明らかにし、その診断アルゴリズムと小腸内視鏡の役割について概説する。(著者抄録)
-
Gut and liver 7(4) 486-91 2013年7月 査読有りBackground/Aims: To confirm the feasibility of using newly developed endoscopic ultrasound (EUS) with Zone sonography (TM) technology (ZST; Fujifilm Corp.). Methods: Seventy-five patients with pancreatic disorders were enrolled: 45 with intraductal papillary mucinous neoplasm; 15 with ductal carcinoma; five with neuroendocrine tumors; three with serous cystic neoplasms; and seven with simple cysts. The endoscopes used were EG-53OUR2 and EG-53OUT2 (Fujifilm Corp.). Two items were evaluated: visualization depth among four frequencies and image quality after automatic adjustment of sound speed (AASS), assessed using a 5-scale Likert scale by two endosonographers blinded to disease status. Because sound speed could be manually controlled, besides PASS, image quality at sound speeds of 1,440 and 1,600 m/sec were also assessed. Results: In all cases, sufficient images were obtained in the range of 3 cm from the EUS probe. Judgments of image quality before AASS were 3.49 +/- 0.50, 3.65 +/- 0.48, respectively. After AASS, A and B scored 4.36 +/- 0.48 and 4.40 +/- 0.49 (p<0.0001). There were significant differences in the data before and after PASS and plus 60 m/sec, but no significant difference between the datasets were seen after PASS and at sound speeds manually set for minus 100 m/sec. Conclusions: EUS with ZST was shown to be feasible in this preliminary experiment. Further evaluation of this novel technology is necessary and awaited.
-
BMC research notes 6(1) 210-210 2013年5月25日 査読有りBackground: Ulcerative colitis (UC) often occurs in women of childbearing age. Compared to Western countries, however, few studies have investigated the impact of UC on the progress of pregnancy in Asian populations. Methods. We retrospectively examined 91 pregnancies in 64 patients with UC experienced at our hospital and related institutions from 1991 to 2011, focusing on the relationship between the progression of UC during pregnancy, progress of the pregnancy itself, and the treatment of UC. Results: In 80 of 91 pregnancies the patient had already been diagnosed with UC at the time she became pregnant, of whom 31 (38.8%) experienced exacerbation during pregnancy. Regarding severity, moderate or severe active-stage disease during pregnancy was seen in 13.7% of those who had been in remission at the onset of pregnancy versus 58.6% of those who had been in the active stage at onset (OR 8.9: 95%CI 3.0∼26.4 P< 0.01). The incidence of miscarriage or abortion was 9.8% in pregnancies in which UC was in remission at onset versus 31% in those in which it was in the active stage at onset (OR 4.1: 95%CI 1.2∼13.9 P=0.02). Among patients, 62.5% were receiving pharmaceutical treatment at onset of pregnancy. Exacerbation during pregnancy occurred in 26.5% of the group who continued to receive the same treatment during pregnancy versus 56.3% of those with a dose decrease or discontinuation after onset (OR 3.6: 95%CI 1.0∼12.4 P=0.04). Conclusions: UC patients wishing to conceive should do so when in remission and continue appropriate pharmaceutical treatment during pregnancy. © 2013 Ujihara et al. licensee BioMed Central Ltd.
-
胃と腸 48(4) 432-438 2013年4月当科でカプセル内視鏡検査(capsule endoscopy;CE)を行った症例のうち,最終的に小腸腫瘍と診断されたのは100例で,多発が67例,単発が33例であった.それらのCEによる存在診断は100例中90例(90%)で可能であった.見逃された10例では2例が多発例で,十二指腸や回腸末端といったCEが急に進むことがある部位の病変であった.単発例の見逃しは,2cm未満の病変が多かった.粘膜下腫瘍の診断は難しいときがあるが,粘膜下腫瘍と壁外圧排との鑑別ポイントはbridging fold,腫瘍表面の緊満感と亜有茎性の外観である.(著者抄録)
-
胃と腸 48(4) 493-498 2013年4月海外では,2006年に第1世代の大腸カプセル内視鏡(PillCam COLON,ギブン・イメージング社製)が,その後,2009年には第2世代の大腸カプセル内視鏡(PillCam COLON 2)が登場した.第2世代のPillCam COLON 2(ギブン・イメージング社製)は視野角が172°で電池寿命も大幅に延長された.この第2世代の大腸カプセル内視鏡は,ゆっくり進むときは従来どおり4枚/秒の頻度で,速く進むときは35枚/秒の頻度で撮影される(AFR:adaptive frame rate).これまでの研究によると,第2世代の大腸用カプセル内視鏡の6mm以上のポリープに対する感度は,およそ80%台(84〜89%)である.苦痛なく受けられるイメージの大腸カプセル内視鏡は,大腸癌検診の受診率向上の1つの契機になる可能性を有する.本邦に大腸カプセル内視鏡が導入されるのは間近である.一刻も早い登場が待ち望まれる.(著者抄録)
-
Gastroenterological Endoscopy 55(Suppl.1) 959-959 2013年4月
書籍等出版物
46講演・口頭発表等
430-
JDDW2024 第108回日本消化器内視鏡学会 2024年11月1日
-
第62回日本小腸学会学術集会 2024年10月19日
担当経験のある科目(授業)
7所属学協会
12共同研究・競争的資金等の研究課題
31-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2025年3月
-
厚生労働省 先進医療B 2021年2月 - 2024年6月
-
国立研究開発法人日本医療研究開発機構（AMED) 令和6年度 医療機器等研究成果展開事業（開発実践タイプ） 2024年6月
-
国立研究開発法人日本医療研究開発機構（AMED) 令和３年度難治性疾患実用化研究事業 2021年5月 - 2024年3月